$270 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 64 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 31.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | Celgene Corp | $13,173,000 | -40.7% | 142,522 | -39.5% | 4.88% | -40.5% |
| STML | Sell | Stemline Therapeutics Inc | $11,402,000 | +11.4% | 744,245 | -6.5% | 4.23% | +11.9% |
| REGN | Sell | Regeneron Pharmaceuticals | $7,299,000 | -43.8% | 23,330 | -26.2% | 2.71% | -43.6% |
| INCY | Sell | Incyte Corp | $6,711,000 | -23.1% | 79,000 | -22.2% | 2.49% | -22.8% |
| KALV | Sell | Kalvista Pharmaceuticals Inc | $4,165,000 | -31.3% | 187,599 | -12.0% | 1.54% | -31.1% |
| GWPH | Sell | GW Pharmaceuticals Plcads | $1,897,000 | -33.0% | 11,000 | -34.5% | 0.70% | -32.8% |
| STRO | Sell | SUTRO BIOPHARMA INC | $1,642,000 | -1.7% | 145,154 | -1.0% | 0.61% | -1.3% |
| ALKS | Sell | ALKERMES PLC | $1,582,000 | -81.4% | 70,000 | -70.0% | 0.59% | -81.3% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $1,415,000 | -80.4% | 53,000 | -80.3% | 0.52% | -80.3% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $1,123,000 | -29.4% | 10,900 | -49.8% | 0.42% | -29.1% |
| AKCA | Sell | AKCEA THERAPEUTICS INC | $743,000 | -64.8% | 31,723 | -57.5% | 0.28% | -64.7% |
| ZGNX | Sell | Zogenix Inc | $687,000 | -86.6% | 14,400 | -84.5% | 0.26% | -86.5% |
| SUPN | Sell | Supernus Pharmaceuticals Inc | $659,000 | -79.1% | 19,953 | -77.8% | 0.24% | -79.0% |
| RDUS | Sell | Radius Health Inc | $414,000 | -80.4% | 17,000 | -83.9% | 0.15% | -80.4% |
| RTRX | Sell | Retrophin Inc | $362,000 | -92.3% | 18,000 | -91.3% | 0.13% | -92.3% |
| MGNX | Exit | MACROGENICS INC | $0 | – | -19,000 | -100.0% | -0.13% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -32,500 | -100.0% | -0.45% | – |
| ARRY | Exit | Array Biopharma Inc | $0 | – | -72,500 | -100.0% | -0.65% | – |
| HZNP | Exit | Horizon Pharma Plc | $0 | – | -128,000 | -100.0% | -1.25% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTD | $0 | – | -145,000 | -100.0% | -2.08% | – |
| ENTA | Exit | Enanta Pharmaceuticals Inc | $0 | – | -61,000 | -100.0% | -2.15% | – |
| AERI | Exit | Aerie Pharmaceuticals Inc | $0 | – | -151,117 | -100.0% | -2.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.